Large Enterprises – Page 33 – GSS EU Science Funding Gateway

admin

2 years ago

The Silver Deal – Person-centred health and care in European regions

admin

2 years ago

The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution

admin

2 years ago

Tackling high-burden for patients, under-researched medical conditions

admin

2 years ago

Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders

admin

2 years ago

Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)

admin

2 years ago

Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

admin

2 years ago

Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness

admin

2 years ago

Health (Cluster 1) (2021-2027)

admin

2 years ago

Erasmus+ Programme – KA1 Learning mobility

admin

2 years ago

EU Funding Programmes

Dissemination & Valorisation

Innovation & Strategy Advisory

Specialised COST Action Deliverables

EU Funding Programmes

Dissemination & Valorisation

Innovation & Strategy Advisory

EU Funding Programmes

Dissemination & Valorisation

Innovation & Strategy Advisory

Specialised COST Action Deliverables

EU Funding Programmes

Dissemination & Valorisation

Innovation & Strategy Advisory

Looking for collaboration?

Archive

admin

The Silver Deal – Person-centred health and care in European regions

admin

The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution

admin

Tackling high-burden for patients, under-researched medical conditions

admin

Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders

admin

Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)

admin

Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

admin

Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness

admin

Key Action 1 (KA1) – Learning mobility of individuals

Case studies

About Us

Company